Mesalazine for People with Diverticular Disease: A Systematic Review of Randomized Controlled Trials

Table 1

Characteristics of the randomized controlled trials comparing mesalazine with control interventions for diverticular disease.

Study (reference)

Year

Number of patients

Mean age (SD)

Procedure used for diagnosis of diverticular disease

Characteristics of diverticular disease

First diagnosis of diverticular disease ()

Mean time from last episode of diverticular disease (SD), days

Characteristics of experimental treatment (mesalazine)

Characteristics of control interventions

Treatment duration, months

Follow-up duration, months

Endoscopy

Radiologic imaging

Subtype

Activity

Daily dose, mg

Mode of administration

Type

Daily dose

Mode of administration

Trespi et al. [22]

1999

166

61.4 (6.4)

√

√

Acute uncomplicated diverticulitis

Remission

21.0

na

800

Continuous

No treatment

/

/

2

48

Tursi et al. [23]

2006

67.5

√

Symptomatic uncomplicated diverticular disease

Remission

31.1

na

1600

Continuous

Lactobacillus casei sub-species DG

16 billion viable lyophilized bacteria

Cyclic (15 days/month)

12

12

Comparato et al. a [24]

2007

67.3 (10.2)

√

√

Symptomatic uncomplicated diverticular disease

Active

na

na

800 or 1600

Cyclic (10 days/month)

Rifaximin

400 or 800 mg

Cyclic (10 days/month)

6

6

Comparato et al. b [25]

2007

65.0 (7.2)–67.4 (9.1)

√

√

Symptomatic uncomplicated diverticular disease

Active

na

na

800 or 1600

Cyclic (10 days/month)

Rifaximin

400 or 800 mg

Cyclic (10 days/month)

12

12

Smith et al. [26]

2012

43

na

√

Symptomatic uncomplicated diverticular disease

Active

na

na

3000

Continuous

Placebo

/

Continuous

3

3

Kruis et al. [27]

2013

123

63.0 (8.6)- 62.0 (8.6)

√

Symptomatic uncomplicated diverticular disease

Active

na

na

3000

Continuous

Placebo

/

Continuous

6 weeks

6 weeks

Parente et al. [28]

2013

61.5 (11.1)

√

√

Acute uncomplicated diverticulitis

Remission

100.0

<12 months

1600

Cyclic (10 days/month)

Placebo

/

Cyclic (10 days/month)

24

24

Stollman et al. [29]

2013

56.1 (11.1)- 57.7 (12.8)

√

Acute uncomplicated diverticulitis

Active

49.6

na

2400

Continuous

Placebo

/

Continuous

3

12

Tursi et al. [30]

2013

60-

√

Symptomatic uncomplicated diverticular disease

Remission

54.3

na

1600

Cyclic (10 days/month)

Placebo; Lactobacillus casei sub-species DG

/; 24 billion viable lyophilized bacteria

Cyclic (10 days/month); Cyclic (10 days/month)

12

12

PREVENT1 [31]

2014

590

55.3 (11.4)

√

√

Acute uncomplicated diverticulitis

Remission

58.1

1200 or 2400 or 4800

Continuous

Placebo

/

Continuous

24

24

PREVENT2 [31]

2014

592

56.1 (11.0)

√

√

Acute uncomplicated diverticulitis

Remission

59.7

1200 or 2400 or 4800

Continuous

Placebo

/

Continuous

24

24

SAG-37 [32]

2017

345

58.6 (9.3)

√

Acute uncomplicated diverticulitis

Remission

55.0

87.0 (48.0)

3000

Continuous

Placebo

/

Continuous

12

12

SAG-51 [32]

2017

330

55.4 (10.6)

√

Acute uncomplicated diverticulitis

Remission

51.2

89.0 (44.0)

1500 or 3000

Continuous

Placebo

/

Continuous

24

24

SD, standard deviation; na, not assessed.
study includes 3 arms (mesalazine, probiotic, and mesalazine plus probiotic), but only the mesalazine and probiotic arms were considered in this analysis.
participants were included in both studies.
participants were randomized; 4 were excluded for no study drug assumption, but there is no mention on their study group. Thus, only 92 participants are included in our analysis.
study includes 3 arms (mesalazine, placebo, and mesalazine plus probiotic), but only the mesalazine and placebo arms were considered in this analysis.
study includes 4 arms (mesalazine, probiotic, mesalazine plus probiotic, and placebo), but only the mesalazine, probiotic, and placebo arms were considered in this analysis.
value.
same publication includes two randomized trials with identical study design.
same publication includes two randomized trials.